Ionis Q2 2026: TRYNGOLZA Launch Gains Traction, Pipeline Milestones on Track, Cash $2.1B
IONS sits 41% above its 52-week low of $40.03.
Summary
Ionis reported Q2 2026 earnings with $268M in revenue and a $115M net loss. The TRYNGOLZA sHTG launch is gaining traction, DAWNZERA sales jumped 63% QoQ, and 2026 guidance was reaffirmed. Key catalysts ahead include approval decisions for zilganersen and bepirovirsen, as well as pelacarsen Phase 3 data.
Key Events · Earnings and Guidance · IONS
-
Q2 2026 Financial Results
Total revenue reached $268M, with a net loss of $115M and cash of $2.1B. Excluding a one-time sapablursen upfront payment in Q2 2025, revenue grew 56%.
-
TRYNGOLZA sHTG Launch Momentum
Following its late-June sHTG approval, TRYNGOLZA generated $5M in Q2 net product sales. Full-year 2026 sales guidance remains $100-110M.
-
DAWNZERA Sales Growth
DAWNZERA net product sales hit $26M in Q2, a 63% increase from Q1 2026. Full-year guidance of $110-120M was reaffirmed.
-
Upcoming Regulatory Catalysts
The PDUFA date for zilganersen in Alexander disease is September 22, 2026; for bepirovirsen in chronic hepatitis B, it is October 26, 2026.
Analysis · IONS · Life Sciences
Ionis posted Q2 2026 revenue of $268M alongside a net loss of $115M, reflecting stepped-up commercialization spending for TRYNGOLZA and DAWNZERA. The early sHTG launch of TRYNGOLZA is building momentum, while DAWNZERA sales climbed 63% quarter-over-quarter. Management reaffirmed its 2026 guidance and pointed to upcoming catalysts: PDUFA dates for zilganersen and bepirovirsen, plus pelacarsen cardiovascular outcomes data. With $2.1B in cash, the company has ample runway to advance its wholly owned pipeline and remains on track for cashflow breakeven by 2028.
At the time of this filing, IONS was trading at $56.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $40.03 to $86.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.